Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

Share Price is delayed by 15 minutes
Get Live Data
630.00    30.00 (5.00%)
Bid:
626.00
Ask:
634.00
Spread: 8.00 (1.278%)
Market Cap: £762.36m
OXB Live PriceLast checked at - London Stock Exchange

Intraday Oxford Biomedica Share Chart

Director Declaration

2 Jul 2025 07:00

RNS Number : 3814P
Oxford Biomedica PLC
02 July 2025
 

 

 

 

OXB Directorship notification under UK Listing Rule 6.4.9R(2)

Oxford, UK - 2 July 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that Mr. Colin Bond, Independent Non-Executive Director, has been appointed as Additional Director (Non-Executive, Independent) of OneSource Specialty Pharma Limited, a company listed at the National Stock Exchange of India Limited (NSE) and Bombay Stock Exchange Limited (BSE), subject to the approval of the shareholders by way of special resolution expected to be announced on or around 1 August 2025.

 

-Ends-

 

Enquiries:

 

OXB

Natalie Walter, Company Secretary - T: +44 (0) 1865 783 000 / E: cosec@oxb.com

 

About OXB

 

OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.

 

One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

 

OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.

 

OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and Bedford MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RDNRTMATMTIMMRA
Date   Source Headline
28th May 20217:00 amEQSOxford Biomedica (OXB): Driving innovation in a thriving CGT industry
28th May 20217:00 amRNSBlock Listing Application
28th May 20217:00 amRNSResult of AGM
27th May 20217:00 amRNSBoard Change
25th May 20219:21 amRNSDirector/PDMR Shareholding
21st May 202112:46 pmRNSPDMR Dealing
20th May 202111:42 amRNSPDMR Dealings
18th May 20217:00 amRNSOxford Biomedica upgrades financial guidance
10th May 202110:54 amRNSHolding(s) in Company
4th May 202110:29 amRNSTotal Voting Rights
4th May 202110:27 amRNSHoldings in Company
27th Apr 20212:40 pmRNS2020 Annual report and Accounts & AGM Notification
26th Apr 202112:32 pmRNSHolding(s) in Company
15th Apr 20217:00 amRNSFull year results
6th Apr 20217:00 amRNSOXB signs Agreement with Boehringer Ingelheim
1st Apr 202111:04 amRNSTotal Voting Rights
30th Mar 202110:22 amRNSHolding(s) in Company
19th Mar 20217:01 amRNSUpdate on Sanofi Collaboration & License Agreement
15th Mar 202110:03 amRNSNotice of Preliminary Results
1st Mar 20219:36 amRNSTotal Voting Rights
26th Feb 202110:46 amRNSPDMR Dealings / Market Share sale
5th Feb 20211:22 pmRNSHoldings in Company
3rd Feb 20217:00 amRNSBoard Changes
1st Feb 20219:47 amRNSTotal Voting Rights
4th Jan 20212:09 pmRNSBlock Listing Return
4th Jan 20211:41 pmRNSTotal Voting Rights
30th Dec 20209:03 amRNSOXB notes AZ vaccine has been authorised in the UK
1st Dec 202012:17 pmRNSDirector Dealings
1st Dec 20209:02 amRNSTotal Voting Rights
23rd Nov 20208:47 amRNSOXB notes AZD1222 met primary efficacy endpoint
23rd Nov 20207:00 amRNSNon-Executive Director Appointment
9th Nov 20207:00 amRNSOXB and PhoreMost enter gene therapy collaboration
2nd Nov 20209:02 amRNSTotal Voting Rights
30th Oct 20207:00 amRNSAxovant update on AXO-Lenti-PD and virtual R&D day
23rd Oct 202010:27 amRNSDirector Purchase
12th Oct 20205:38 pmRNSHolding(s) in Company
6th Oct 202012:46 pmRNSAxovant update on 2nd cohort of SUNRISE-PD trial
6th Oct 20207:00 amRNSOXB receives approval for fourth suite in Oxbox
5th Oct 202010:59 amEQSEdison Investment Research Limited: Oxford Biomedica (OXB): Vector innovation key to cell and gene evolution
2nd Oct 202011:52 amRNSTotal Voting Rights
29th Sep 20203:51 pmRNSDirector Dealings
24th Sep 20209:36 amRNSDirector/PDMR Shareholding
22nd Sep 202012:54 pmRNSDirector/PDMR Shareholding
17th Sep 20207:00 amRNSInterim Results
1st Sep 20209:33 amRNSTotal Voting Rights
1st Sep 20207:00 amRNSMaster Supply and Development Agreement with AZ
27th Aug 20207:00 amRNSNotice of Interim Results
25th Aug 20204:46 pmRNSBlock listing Application
3rd Aug 20209:41 amRNSTotal Voting Rights
3rd Aug 20207:00 amRNSOXB signs DMLA with Beam Therapeutics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.